A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Completed
Clear Creek Bio, Inc.
Phase 1/Phase 2
A Phase 1b/2a multi-center, open-label, non-randomized study to assess the safety,
tolerability and efficacy of dose-adjusted brequinar in adult subjects with acute myeloid
leukemia (AML). Ribavirin BID may be added to brequinar twice weekly in eligible subjects.
Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19
Completed
Clear Creek Bio, Inc.
Phase 1/Phase 2
This will be a phase 1a randomized, open label, multi-center study with approximately 24
subjects. All subjects will receive standard of care (SOC) per institutional guidelines for
treatment of hospitalized patients with COVID-19 infection. In addition to SOC, the brequinar
group will receive 5 daily doses of brequinar 100 mg.
CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19
Completed
Clear Creek Bio, Inc.
Phase 2
This study will assess the efficacy and safety of DHODHi (brequinar) as an antiviral via 5
days of treatment of participants with positive COVID-19 and at least one symptom of COVI019
in an out-patient setting. The study is multi-center, randomized, and placebo-controlled.
Brequinar Combined With Dipyridamole in Patients With Mild to Moderate SARS-CoV-2 Infection.
Not yet recruiting
Clear Creek Bio, Inc.
Phase 2
A Phase 2 multi-center, assessor-blind, randomized study to assess the safety, tolerability,
and antiviral activity of brequinar in combination with dipyridamole.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
